199 related articles for article (PubMed ID: 23259667)
1. Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study.
Synnestvedt M; Borgen E; Wist E; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Schirmer C; Nesland JM; Naume B
BMC Cancer; 2012 Dec; 12():616. PubMed ID: 23259667
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.
Naume B; Synnestvedt M; Falk RS; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Sommer HH; Sætersdal AB; Rypdal MC; Bendigtsen Schirmer C; Wist EA; Borgen E
J Clin Oncol; 2014 Dec; 32(34):3848-57. PubMed ID: 25366688
[TBL] [Abstract][Full Text] [Related]
3. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.
Mathiesen RR; Borgen E; Renolen A; Løkkevik E; Nesland JM; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Kvalheim G; Lønning PE; Naume B
Breast Cancer Res; 2012 Aug; 14(4):R117. PubMed ID: 22889108
[TBL] [Abstract][Full Text] [Related]
4. Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome.
Tjensvoll K; Oltedal S; Heikkilä R; Kvaløy JT; Gilje B; Reuben JM; Smaaland R; Nordgård O
BMC Cancer; 2012 May; 12():190. PubMed ID: 22640166
[TBL] [Abstract][Full Text] [Related]
5. Comparison of molecular and immunocytochemical methods for detection of disseminated tumor cells in bone marrow from early breast cancer patients.
Gilje B; Nordgård O; Tjensvoll K; Borgen E; Synnestvedt M; Smaaland R; Naume B
BMC Cancer; 2014 Jul; 14():514. PubMed ID: 25023626
[TBL] [Abstract][Full Text] [Related]
6. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients.
Fehm T; Krawczyk N; Solomayer EF; Becker-Pergola G; Dürr-Störzer S; Neubauer H; Seeger H; Staebler A; Wallwiener D; Becker S
Breast Cancer Res; 2008; 10(5):R76. PubMed ID: 18793387
[TBL] [Abstract][Full Text] [Related]
7. The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy.
Hartkopf AD; Taran FA; Wallwiener M; Hagenbeck C; Melcher C; Krawczyk N; Hahn M; Wallwiener D; Fehm T
Breast Cancer Res; 2013; 15(5):R94. PubMed ID: 24099325
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up.
Hoffmann O; Schroer-Zuendorf IA; Kasimir-Bauer S; Oberhoff C; Kimmig R; Heubner M
Arch Gynecol Obstet; 2015 Nov; 292(5):1117-25. PubMed ID: 25986892
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.
Hartkopf AD; Taran FA; Wallwiener M; Hahn M; Becker S; Solomayer EF; Brucker SY; Fehm TN; Wallwiener D
Eur J Cancer; 2014 Oct; 50(15):2550-9. PubMed ID: 25096167
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of CTC and DTC-BM Detection for Adjuvant Therapy Effects and Prognosis Prediction in Early Breast Carcinoma: Results of 8-11 Years of Follow-up Evaluation.
Takeyama H; Shimada T; Kinoshita S; Uchida K
Ann Surg Oncol; 2017 May; 24(5):1227-1233. PubMed ID: 27909824
[TBL] [Abstract][Full Text] [Related]
11. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis.
Hartkopf AD; Brucker SY; Taran FA; Harbeck N; von Au A; Naume B; Pierga JY; Hoffmann O; Beckmann MW; Rydén L; Fehm T; Aft R; Solà M; Walter V; Rack B; Schuetz F; Borgen E; Ta MH; Bittner AK; Fasching PA; Fernö M; Krawczyk N; Weilbaecher K; Margelí M; Hahn M; Jueckstock J; Domschke C; Bidard FC; Kasimir-Bauer S; Schoenfisch B; Kurt AG; Wallwiener M; Gebauer G; Klein CA; Wallwiener D; Janni W; Pantel K
Eur J Cancer; 2021 Sep; 154():128-137. PubMed ID: 34265505
[TBL] [Abstract][Full Text] [Related]
12. Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome.
Synnestvedt M; Borgen E; Schlichting E; Schirmer CB; Renolen A; Giercksky KE; Nesland JM; Naume B
Breast Cancer Res Treat; 2013 Apr; 138(2):485-97. PubMed ID: 23456230
[TBL] [Abstract][Full Text] [Related]
13. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer.
Daskalaki A; Agelaki S; Perraki M; Apostolaki S; Xenidis N; Stathopoulos E; Kontopodis E; Hatzidaki D; Mavroudis D; Georgoulias V
Br J Cancer; 2009 Aug; 101(4):589-97. PubMed ID: 19623181
[TBL] [Abstract][Full Text] [Related]
14. NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients.
Borgen E; Rypdal MC; Sosa MS; Renolen A; Schlichting E; Lønning PE; Synnestvedt M; Aguirre-Ghiso JA; Naume B
Breast Cancer Res; 2018 Oct; 20(1):120. PubMed ID: 30322396
[TBL] [Abstract][Full Text] [Related]
15. Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study.
Hoffmann O; Aktas B; Goldnau C; Heubner M; Oberhoff C; Kimmig R; Kasimir-Bauer S
Anticancer Res; 2011 Oct; 31(10):3623-8. PubMed ID: 21965788
[TBL] [Abstract][Full Text] [Related]
16. Disseminated tumor cells as a monitoring tool for adjuvant therapy in patients with primary breast cancer.
Gruber I; Fehm T; Taran FA; Wallwiener M; Hahn M; Wallwiener D; Krawzyck N; Hoffmann J; Hartkopf AD
Breast Cancer Res Treat; 2014 Apr; 144(2):353-60. PubMed ID: 24554386
[TBL] [Abstract][Full Text] [Related]
17. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.
Banys M; Solomayer EF; Gebauer G; Janni W; Krawczyk N; Lueck HJ; Becker S; Huober J; Kraemer B; Wackwitz B; Hirnle P; Wallwiener D; Fehm T
BMC Cancer; 2013 Oct; 13():480. PubMed ID: 24128322
[TBL] [Abstract][Full Text] [Related]
18. The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy.
Wimberger P; Blohmer JU; Krabisch P; Link T; Just M; Sinn BV; Simon E; Solbach C; Fehm T; Denkert C; Kühn C; Rhiem K; Tesch H; Kümmel S; Petzold A; Stötzer O; Meisel C; Kuhlmann JD; Nekljudova V; Loibl S
Breast Cancer Res; 2023 Mar; 25(1):32. PubMed ID: 36978142
[TBL] [Abstract][Full Text] [Related]
19. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.
Aft R; Naughton M; Trinkaus K; Watson M; Ylagan L; Chavez-MacGregor M; Zhai J; Kuo S; Shannon W; Diemer K; Herrmann V; Dietz J; Ali A; Ellis M; Weiss P; Eberlein T; Ma C; Fracasso PM; Zoberi I; Taylor M; Gillanders W; Pluard T; Mortimer J; Weilbaecher K
Lancet Oncol; 2010 May; 11(5):421-8. PubMed ID: 20362507
[TBL] [Abstract][Full Text] [Related]
20. Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?
Chebouti I; Blassl C; Wimberger P; Neubauer H; Fehm T; Kimmig R; Kasimir-Bauer S
Oncotarget; 2016 May; 7(18):26454-64. PubMed ID: 27049920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
